Genetic Testing for Statin-Induced Myopathy

Last Review Date: November 10, 2017  Number: MG.MM.LA.23C2v2

Definitions

Statin-induced myopathy is a side effect that occurs in susceptible individuals taking statin for the treatment of hypercholesterolemia and coronary artery disease. Inherited variations on the SLCO1B1 gene appear to increase the risk of statin-induced myopathy and reduce effectiveness of statin therapy. Statin-induced myopathy is categorized into statin-induced myalgia, statin-induced myositis and statin-induced rhabdomyolysis.

Guideline

Genetic testing of variants in the SLCO1B1 gene to identify individuals at increased risk of statin-induced myopathy is considered investigational and not medically necessary.

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81400</td>
<td>Molecular pathology procedure, Level 1 (eg, identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve analysis) (Revision eff. 01/01/2018)</td>
</tr>
</tbody>
</table>

References


